Natural substances and Alzheimer's disease: From preclinical studies to evidence based medicine

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 616-624

  Mancuso, Cesare ^a   Siciliano, Raffaella ^a   Barone, Eugenio ^a   Preziosi, Paolo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acetyl l carnitine; Alzheimer's disease; Curcumin; Ginkgo biloba; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; AMYLOID BETA PROTEIN; CARNITINE; CURCUMIN; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; GINKGOSELECT; LACTATE DEHYDROGENASE; OMEPRAZOLE; PHENYTOIN; PIPERINE; PLACEBO; TRAZODONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALZHEIMER DISEASE; CELLULAR STRESS RESPONSE; CHRONIC DRUG ADMINISTRATION; COMA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; FATIGUE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL RESPIRATION; MUSCLE CRAMP; NAUSEA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ALZHEIMER DISEASE; ANTIOXIDANTS; BIOLOGICAL AGENTS; EVIDENCE-BASED MEDICINE; HUMANS;

GINKGO BILOBA;

EID: 84858155062     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.09.004     Document Type: Review

References (123)

1. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
2. Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010, 23:213-227.
3. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
4. Mayeux R. Early Alzheimer's disease. N. Engl. J. Med. 2010, 362:2194-2201.
5. Seripa D., Panza F., Franceschi M., D'Onofrio G., Solfrizzi V., Dallapiccola B., Pilotto A. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res. Rev. 2009, 8:214-236.
6. Schipper H.M. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol. Aging 2011, 32:778-790.
7. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
8. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., Dinkova Kostova A.T., Calabrese V. Natural antioxidants in Alzheimer's disease. Expert. Opin. Invest. Drugs 2007, 16:1921-1931.
9. Calabrese V., Cornelius C., Mancuso C., Barone E., Calafato S., Bates T., Rizzarelli E., Kostova A.T. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front. Biosci. 2009, 14:376-397.
10. Barone E., Calabrese V., Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 2009, 10:97-108.
11. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:341-353.
12. Mancuso C., Siciliano R., Barone E., Butterfield D.A., Preziosi P. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert. Opin. Invest. Drugs 2011, 20:1243-1261.
13. Sultana R., Perluigi M., Butterfield D.A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118:131-150.
14. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
15. Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 2007, 43:658-677.
16. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
17. Shelat P.B., Chalimoniuk M., Wang J.H., Strosznajder J.B., Lee J.C., Sun A.Y., Simonyi A., Sun G.Y. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J. Neurochem. 2008, 106:45-55.
18. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 2007, 27:5394-5404.
19. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41:242-247.
20. Sultana R., Banks W.A., Butterfield D.A. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J. Neurosci. Res. 2010, 88:469-477.
21. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
22. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 2006, 72:1439-1452.
23. Tirkey N., Kaur G., Vij G., Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. 2005, 5:15.
24. Sharma R.A., Gescher A.J., Steward W.P. Curcumin: the story so far. Eur. J. Cancer 2005, 41:1955-1968.
25. Ravindranath V., Chandrasekhara N. Metabolism of curcumin-studies with [3H]curcumin. Toxicology 1981, 22:337-344.
26. Ravindranath V., Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980, 16:259-265.
27. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64:353-356.
28. Maiti K., Mukherjee K., Gantait A., Saha B.P., Mukherjee P.K. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 2007, 330:155-163.
29. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 2007, 60:171-177.
30. Kakkar V., Singh S., Singla D., Sahwney S., Chauhan A.S., Singh G., Kaur I.P. Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2010, 878:3427-3431.
31. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., Aggarwal B.B. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol. 2010, 79:330-338.
32. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 2009, 37:223-230.
33. Zhou S., Lim L.Y., Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab. Rev. 2004, 36:57-104.
34. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., Steward W.P., Gescher A.J., Berry D.P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 2004, 90:1011-1015.
35. Lao C.D., Ruffin M.T.t., Normolle D., Heath D.D., Murray S.I., Bailey J.M., Boggs M.E., Crowell J., Rock C.L., Brenner D.E. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006, 6:10.
36. Baum L., Lam C.W., Cheung S.K., Kwok T., Lui V., Tsoh J., Lam L., Leung V., Hui E., Ng C., Woo J., Chiu H.F., Goggins W.B., Zee B.C., Cheng K.F., Fong C.Y., Wong A., Mok H., Chow M.S., Ho P.C., Ip S.P., Ho C.S., Yu X.W., Lai C.Y., Chan M.H., Szeto S., Chan I.H., Mok V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 2008, 28:110-113.
37. Somparn P., Phisalaphong C., Nakornchai S., Unchern S., Morales N.P. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. 2007, 30:74-78.
38. Ireson C.R., Jones D.J., Orr S., Coughtrie M.W., Boocock D.J., Williams M.L., Farmer P.B., Steward W.P., Gescher A.J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 2002, 11:105-111.
39. Mancuso C., Barone E. Curcumin in clinical practice: myth or reality?. Trends Pharmacol. Sci. 2009, 30:333-334.
40. Volak L.P., Ghirmai S., Cashman J.R., Court M.H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab. Dispos. 2008, 36:1594-1605.
41. Hayeshi R., Mutingwende I., Mavengere W., Masiyanise V., Mukanganyama S. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol. 2007, 45:286-295.
42. Appiah-Opong R., Commandeur J.N., van Vugt-Lussenburg B., Vermeulen N.P. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 2007, 235:83-91.
43. Correia M.A. Drug Biotransformation 2007, The McGraw-Hill Companies. 10th Edition ed.
44. Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., McLeod H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 2005, 44:279-304.
45. Roman G.C., Rogers S.J. Donepezil: a clinical review of current and emerging indications. Expert. Opin. Pharmacother. 2004, 5:161-180.
46. Lockhart I.A., Mitchell S.A., Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement. Geriatr. Cogn. Disord. 2009, 28:389-403.
47. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10:6847-6854.
48. Burgos-Moron E., Calderon-Montano J.M., Salvador J., Robles A., Lopez-Lazaro M. The dark side of curcumin. Int. J. Cancer 2010, 126:1771-1775.
49. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., DeKosky S.T. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch. Neurol. 2000, 57:824-830.
50. Kim D.S., Park S.Y., Kim J.K. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci. Lett. 2001, 303:57-61.
51. Ahmed T., Gilani A.H., Hosseinmardi N., Semnanian S., Enam S.A., Fathollahi Y. Curcuminoids rescue long-term potentiation impaired by amyloid peptide in rat hippocampal slices. Synapse 2011, 65:572-582.
52. Kim J., Lee H.J., Lee K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem. 2010, 112:1415-1430.
53. Piper J.T., Singhal S.S., Salameh M.S., Torman R.T., Awasthi Y.C., Awasthi S. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int. J. Biochem. Cell Biol. 1998, 30:445-456.
54. Calabrese V., Bates T.E., Mancuso C., Cornelius C., Ventimiglia B., Cambria M.T., Di Renzo L., De Lorenzo A., Dinkova-Kostova A.T. Curcumin and the cellular stress response in free radical-related diseases. Mol. Nutr. Food Res. 2008, 52:1062-1073.
55. Mancuso C., Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab. 2009, 10:579-594.
56. Calabrese V., Cornelius C., Trovato A., Cavallaro M., Mancuso C., Di Rienzo L., Condorelli D., De Lorenzo A., Calabrese E.J. The hormetic role of dietary antioxidants in free radical-related diseases. Curr. Pharm. Des. 2010, 16:877-883.
57. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
58. Garcia-Alloza M., Borrelli L.A., Rozkalne A., Hyman B.T., Bacskai B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 2007, 102:1095-1104.
59. Baum L., Cheung S.K., Mok V.C., Lam L.C., Leung V.P., Hui E., Ng C.C., Chow M., Ho P.C., Lam S., Woo J., Chiu H.F., Goggins W., Zee B., Wong A., Mok H., Cheng W.K., Fong C., Lee J.S., Chan M.H., Szeto S.S., Lui V.W., Tsoh J., Kwok T.C., Chan I.H., Lam C.W. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 2007, 56:509-514.
60. Rossi R., Basilico F., Rossoni G., Riva A., Morazzoni P., Mauri P.L. Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex. J. Pharm. Biomed. Anal. 2009, 50:224-227.
61. Singh B., Kaur P., Gopichand, Singh R.D., Ahuja P.S. Biology and chemistry of Ginkgo biloba. Fitoterapia 2008, 79:401-418.
62. Chen Z.P., Sun J., Chen H.X., Xiao Y.Y., Liu D., Chen J., Cai H., Cai B.C. Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats. Fitoterapia 2010, 81:1045-1052.
63. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet 1992, 340:1136-1139.
64. Moreau J.P., Eck C.R., McCabe J., Skinner S. Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat. Presse Med. 1986, 15:1458-1461.
65. Suehiro M., Simpson N.R., Underwood M.D., Castrillon J., Nakanishi K., van Heertum R. In vivo biodistribution of ginkgolide B, a constituent of Ginkgo biloba, visualized by MicroPET. Planta Med. 2005, 71:622-627.
66. Rangel-Ordonez L., Noldner M., Schubert-Zsilavecz M., Wurglics M. Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761(R). Planta Med. 2010, 76:1683-1690.
67. Mauri P., Simonetti P., Gardana C., Minoggio M., Morazzoni P., Bombardelli E., Pietta P. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun. Mass Spectrom. 2001, 15:929-934.
68. Ude C., Paulke A., Noldner M., Schubert-Zsilavecz M., Wurglics M. Plasma and brain levels of terpene trilactones in rats after an oral single dose of standardized Ginkgo biloba extract EGb 761(R). Planta Med. 2011, 77:259-264.
69. Yin O.Q., Tomlinson B., Waye M.M., Chow A.H., Chow M.S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004, 14:841-850.
70. Kupiec T., Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J. Anal. Toxicol. 2005, 29:755-758.
71. Galluzzi S., Zanetti O., Binetti G., Trabucchi M., Frisoni G.B. Coma in a patient with Alzheimer's disease taking low dose trazodone and Ginkgo biloba. J. Neurol. Neurosur. Ps. 2000, 68:679-680.
72. Bridi R., Crossetti F.P., Steffen V.M., Henriques A.T. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001, 15:449-451.
73. 2+ dyshomeostasis that is blocked by EGb761. Neurochem. Int. 2010, 56:893-905.
74. Shi C., Liu J., Wu F., Yew D.T. Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice. Int. J. Mol. Sci. 2010, 11:107-123.
75. Samhan-Arias A.K., Martin-Romero F.J., Gutierrez-Merino C. Kaempferol blocks oxidative stress in cerebellar granule cells and reveals a key role for reactive oxygen species production at the plasma membrane in the commitment to apoptosis. Free Radic Biol. Med. 2004, 37:48-61.
76. Colciaghi F., Borroni B., Zimmermann M., Bellone C., Longhi A., Padovani A., Cattabeni F., Christen Y., Di Luca M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol. Dis. 2004, 16:454-460.
77. Augustin S., Huebbe P., Matzner N., Augustin K., Schliebs R., Cermak R., Wolffram S., Rimbach G. Ginkgo biloba extract and its flavonol and terpenelactone fractions do not affect beta-secretase mRNA and enzyme activity levels in cultured neurons and in mice. Planta Med. 2008, 74:6-13.
78. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12197-12202.
79. Bastianetto S., Ramassamy C., Dore S., Christen Y., Poirier J., Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 2000, 12:1882-1890.
80. Ansari M.A., Abdul H.M., Joshi G., Opii W.O., Butterfield D.A. Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J. Nutr. Biochem. 2009, 20:269-275.
81. Bastianetto S., Zheng W.H., Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J. Neurochem. 2000, 74:2268-2277.
82. Smith J.V., Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J. Alzheimers Dis. 2003, 5:287-300.
83. Tchantchou F., Xu Y., Wu Y., Christen Y., Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J. 2007, 21:2400-2408.
84. Shah Z.A., Nada S.E., Dore S. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection. Neuroscience 2011, 180:248-255.
85. Saleem S., Zhuang H., Biswal S., Christen Y., Dore S. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke 2008, 39:3389-3396.
86. Kanowski S., Herrmann W.M., Stephan K., Wierich W., Horr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996, 29:47-56.
87. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997, 278:1327-1332.
88. Maurer K., Ihl R., Dierks T., Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J. Psychiatr. Res. 1997, 31:645-655.
89. Le Bars P.L., Kieser M., Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 2000, 11:230-237.
90. Kanowski S., Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003, 36:297-303.
91. van Dongen M.C., van Rossum E., Kessels A.G., Sielhorst H.J., Knipschild P.G. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc. 2000, 48:1183-1194.
92. van Dongen M., van Rossum E., Kessels A., Sielhorst H., Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J. Clin. Epidemiol. 2003, 56:367-376.
93. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2005, 2:541-551.
94. DeKosky S.T., Williamson J.D., Fitzpatrick A.L., Kronmal R.A., Ives D.G., Saxton J.A., Lopez O.L., Burke G., Carlson M.C., Fried L.P., Kuller L.H., Robbins J.A., Tracy R.P., Woolard N.F., Dunn L., Snitz B.E., Nahin R.L., Furberg C.D. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.
95. Snitz B.E., O'Meara E.S., Carlson M.C., Arnold A.M., Ives D.G., Rapp S.R., Saxton J., Lopez O.L., Dunn L.O., Sink K.M., DeKosky S.T. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302:2663-2670.
96. Weinmann S., Roll S., Schwarzbach C., Vauth C., Willich S.N. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010, 10:14.
97. Evans A.M., Fornasini G. Pharmacokinetics of l-carnitine. Clin. Pharmacokinet. 2003, 42:941-967.
98. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann. N. Y. Acad. Sci. 2004, 1033:30-41.
99. Brass E.P., Hoppel C.L., Hiatt W.R. Effect of intravenous l-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. Clin. Pharmacol. Ther. 1994, 55:681-692.
100. Gross C.J., Savaiano D.A. Effect of development and nutritional state on the uptake, metabolism and release of free and acetyl-l-carnitine by the rodent small intestine. Biochim. Biophys. Acta 1993, 1170:265-274.
101. Pace S., Longo A., Toon S., Rolan P., Evans A.M. Pharmacokinetics of propionyl-l-carnitine in humans: evidence for saturable tubular reabsorption. Br. J. Clin. Pharmacol. 2000, 50:441-448.
102. Kwon O.S., Chung Y.B. HPLC determination and pharmacokinetics of endogenous acetyl-l-carnitine (ALC) in human volunteers orally administered a single dose of ALC. Arch. Pharm. Res. 2004, 27:676-681.
103. Friedrich A., Prasad P.D., Freyer D., Ganapathy V., Brust P. Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier. Brain Res. 2003, 968:69-79.
104. Parnetti L., Gaiti A., Mecocci P., Cadini D., Senin U. Pharmacokinetics of IV and oral acetyl-l-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur. J. Clin. Pharmacol. 1992, 42:89-93.
105. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. Effect of aging and acetyl-l-carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria. FEBS Lett. 1994, 350:213-215.
106. Bagetta V., Barone I., Ghiglieri V., Di Filippo M., Sgobio C., Bernardi G., Calabresi P., Picconi B. Acetyl-l-carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008, 55:223-229.
107. McDaniel M.A., Maier S.F., Einstein G.O. "Brain-specific" nutrients: a memory cure?. Nutrition 2003, 19:957-975.
108. Pascale A., Milano S., Corsico N., Lucchi L., Battaini F., Martelli E.A., Trabucchi M., Govoni S. Protein kinase C activation and anti-amnesic effect of acetyl-l-carnitine: in vitro and in vivo studies. Eur. J. Pharmacol. 1994, 265:1-7.
109. Piovesan P., Pacifici L., Taglialatela G., Ramacci M.T., Angelucci L. Acetyl-l-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 1994, 633:77-82.
110. Taglialatela G., Navarra D., Cruciani R., Ramacci M.T., Alema G.S., Angelucci L. Acetyl-l-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp. Gerontol. 1994, 29:55-66.
111. Castorina M., Ambrosini A.M., Pacific L., Ramacci M.T., Angelucci L. Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: prevention by acetyl-l-carnitine. Neurochem. Res. 1994, 19:795-798.
112. Abdul H.M., Calabrese V., Calvani M., Butterfield D.A. Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 2006, 84:398-408.
113. Calabrese V., Colombrita C., Sultana R., Scapagnini G., Calvani M., Butterfield D.A., Stella A.M. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid. Redox. Signal 2006, 8:404-416.
114. Rai G., Wright G., Scott L., Beston B., Rest J., Exton-Smith A.N. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr. Med. Res. Opin. 1990, 11:638-647.
115. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., et al. Long-term acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 1991, 41:1726-1732.
116. Thal L.J., Carta A., Clarke W.R., Ferris S.H., Friedland R.P., Petersen R.C., Pettegrew J.W., Pfeiffer E., Raskind M.A., Sano M., Tuszynski M.H., Woolson R.F. A 1-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 1996, 47:705-711.
117. Thal L.J., Calvani M., Amato A., Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000, 55:805-810.
118. Singh S., Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 1995, 270:24995-25000.
119. Nanji A.A., Jokelainen K., Tipoe G.L., Rahemtulla A., Thomas P., Dannenberg A.J. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284:G321-G327.
120. Sandur S.K., Ichikawa H., Pandey M.K., Kunnumakkara A.B., Sung B., Sethi G., Aggarwal B.B. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic. Biol. Med. 2007, 43:568-580.
121. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic. Biol. Med. 2000, 28:1303-1312.
122. Balogun E., Hoque M., Gong P., Killeen E., Green C.J., Foresti R., Alam J., Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371:887-895.
123. Scapagnini G., Colombrita C., Amadio M., D'Agata V., Arcelli E., Sapienza M., Quattrone A., Calabrese V. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox Signal 2006, 8:395-403.